|
DOSAGE
|
1gtt q1hr into conjunctival sac during the day and q2hr in PM initially. Taper to q4hr when improved. Then TID or QID to control symptoms
|
|
The duration of treatment will vary with the type of lesion and may extend from a few days to several weeks, according to therapeutic response. Relapses, more common in chronic active lesions than in self-limited conditions, usually respond to retreatment.
|
|
GENERIC
|
prednisolone sodium phosphate 1.0%
|
|
SIZE
|
5mL,10mL,15mL
|
|
INDICATIONS
|
Prednisolone Sodium Phosphate Ophthalmic Solution, 1% or 1/8% is for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation, corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.
|
|
Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, is recommended for moderate to severe inflammations, particularly when unusually rapid control is desired. In stubborn cases of anterior segment eye disease, systemic adrenocortical hormone therapy may be required. When deeper ocular structures are involved, systemic therapy is necessary.
|
|
MECHANISM OF ACTION
|
Ketone based, phosphate corticosteroid
|
|
MICROBIOLOGY
|
Anti-inflammatory. Inhibits phospholipase A2 blocking both arms of inflammatory cascade. Prednisolone sodium phosphate causes inhibition of inflammatory response to inciting agents of mechanical, chemical, or immunological nature. No generally accepted explanation of this steroid property has been advanced.
|
|
CONTRAINDICATIONS & WARNINGS
|
The use of this preparation is contraindicated in the presence of: Acute superficial herpes simplex keratitis, Fungal diseases of ocular structures, Acute infectious stages of vaccinia, varicella and most other viral diseases of the cornea and conjunctiva, Tuberculosis of the ey, Hypersensitivity to a component of this medication. The use of this preparation is always contraindicated after uncomplicated removal of a superficial corneal foreign body.
|
|
PEDIATRIC USE
|
Safety and effectiveness in pediatric patients have not been established.
|
|
PREGNANCY
|
Pregnancy category C | Animal reproductive studies have not been conducted with prednisolone sodium phosphate. It is also not known whether prednisolone sodium phosphate can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Prednisolone sodium phosphate should be given to a pregnant woman only if clearly needed. The effect of prednisolone sodium phosphate on the later growth, development and functional maturation of the child is unknown.
|
|
NOTE
|
Prolonged use may result in elevated intraocular pressure and/or glaucoma, damage to the optic nerve, defects in visual acuity and fields of vision, posterior subcapsular cataract formation, or may aid in the establishment of secondary ocular infections from pathogens liberated from ocular tissues. In those diseases causing thinning of the cornea or sclera, perforation has been known to occur with the use of topical steroids. Acute purulent untreated infection of the eye may be masked or activity enhanced by presence of steroid medication. Viral, bacterial, and fungal infections of the cornea may be exacerbated by the application of steroids.
|
|
AK-Pred (Akorn), Inflamase Forte (Novartis), Poor penetration compared to suspension so generally used for surface inflammation.
|
